Request Demo
Last update 12 Sep 2026
Insulin aspart biosimilar(Zhuhai United Laboratories Holding Ltd.)
Last update 12 Sep 2026
Overview
Basic Info
Drug Type Biosimilar, Peptide Hormone |
Synonyms Ublin, 联邦优倍灵 |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (14 Jul 2021), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 4857
The sequence is quoted from: *****
Sequence Code 31953
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Insulin aspart biosimilar(Zhuhai United Laboratories Holding Ltd.)NCT07600944
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Insulin Aspart Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers: A Single-Center, Randomized, Double-blinded, Two-Treatment, Two-period, Two-sequence Crossover Study
CTR20160095
采用葡萄糖钳夹技术在健康男性受试者中进行 联邦制药门冬胰岛素注射液的药代动力学（PK） 和药效动力学（PD）研究
[Translation] A pharmacokinetic (PK) and pharmacodynamic (PD) study of the insulin aspart injection of United Lab in healthy male subjects using glucose clamp technique
100 Clinical Results associated with Insulin aspart biosimilar(Zhuhai United Laboratories Holding Ltd.)
Login to view more data
100 Translational Medicine associated with Insulin aspart biosimilar(Zhuhai United Laboratories Holding Ltd.)
Login to view more data
100 Patents (Medical) associated with Insulin aspart biosimilar(Zhuhai United Laboratories Holding Ltd.)
Login to view more data
100 Deals associated with Insulin aspart biosimilar(Zhuhai United Laboratories Holding Ltd.)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 1 | China | 14 Jul 2021 | |
| Diabetes Mellitus, Type 2 | China | 14 Jul 2021 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus | Phase 1 | China | 04 Mar 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free